NEW YORK (GenomeWeb News) – Qiagen said today it has licensed technology from BioHelix that is used to detect and analyze target molecules.
 
Under the non-exclusive, worldwide agreement, Qiagen will license and supply BioHelix’s Helicase Dependent Amplification technology, which is used to detect and analyze biological target molecules such as DNA and RNA.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.